The research team searched five major databases—PubMed, Embase, Scopus, Web of Science and the Cochrane Central Register—through November 2025, screening more than 2,400 records under PRISMA 2020 guidelines. From that effort, eight unique studies contributing ten distinct comparisons made the final synthesis. Five comparisons came from propensity score-matched observational cohorts, four from nonmatched cohorts, and one from randomized trial data, including prespecified analyses of the FLOW and SOUL trials. The researchers deliberately excluded studies that reported only composite major adverse cardiovascular events, or MACE, insisting instead on separate data for myocardial infarction and stroke—a decision that proved scientifically decisive.

That insistence matters because composite endpoints have long been a blind spot in cardiovascular outcomes research. Myocardial infarction is fundamentally a coronary atherothrombotic event, driven by plaque rupture and clot formation in the heart’s arteries, while stroke is a heterogeneous condition involving both cerebrovascular atherosclerosis and cardioembolic pathways. Pooling these biologically distinct events into a single MACE score can mask divergent treatment effects, much like averaging the temperatures of two different cities. By disaggregating the endpoints, the researchers could ask a sharper question: does dual therapy protect the coronary arteries and the cerebral circulation equally?

The answer, intriguingly, is no. For myocardial infarction, combination therapy was associated with a pooled hazard ratio of 0.79, meaning a 21 percent relative risk reduction compared with monotherapy overall. Yet when the investigators stratified by comparator, a telling pattern emerged: dual therapy significantly outperformed SGLT2 inhibitor monotherapy for MI prevention (hazard ratio 0.74), but showed no statistically significant advantage over GLP-1 receptor agonist monotherapy (hazard ratio 0.80, confidence interval 0.55 to 1.16). In other words, the coronary benefit appears to be carried almost entirely by the GLP-1 receptor agonist component of the combination.

This finding aligns closely with the biology established by landmark cardiovascular outcome trials. GLP-1 receptor agonists exert robust antiatherosclerotic and antiinflammatory effects—improving endothelial function, plaque stability, body weight and blood pressure—making them particularly well suited to preventing atherothrombotic coronary events. In the HARMONY Outcomes trial, for instance, the GLP-1 agonist albiglutide reduced MACE, and among the individual components only myocardial infarction showed a statistically significant reduction. SGLT2 inhibitors, by contrast, deliver their most profound and reproducible benefits in heart failure and kidney protection, with more modest effects on atherosclerotic events. Adding an SGLT2 inhibitor to a patient already on a GLP-1 agonist may therefore offer limited incremental defense against coronary ischemia, because the atherothrombotic pathways are already being substantially modulated.

Stroke told a different and arguably more exciting story. Combination therapy was associated with a 15 percent lower stroke risk overall (hazard ratio 0.85), and unlike the MI findings, this benefit outperformed both individual drug classes: a 27 percent reduction versus SGLT2 inhibitor monotherapy and a statistically significant 8 percent reduction versus GLP-1 receptor agonist monotherapy. The advantage was concentrated in ischemic stroke specifically, with a hazard ratio of 0.67. The researchers propose a dual-pathway synergy: while the GLP-1 agonist stabilizes the cerebrovascular wall against atherosclerosis, the SGLT2 inhibitor contributes hemodynamic offloading, blood pressure lowering and possible antiarrhythmic effects. Supporting this framework, prior mechanistic studies have shown that combining the two agents improves endothelial glycocalyx integrity, pulse wave velocity, central systolic blood pressure and left atrial strain—parameters directly relevant to cardioembolic stroke risk.

Perhaps the most clinically provocative result was the age interaction. The cerebrovascular benefit appeared dramatically stronger in adults aged 65 and older, who showed a remarkable 50 percent relative reduction in stroke risk (hazard ratio 0.50), an effect absent in younger cohorts. The authors note that older adults carry a higher baseline burden of arterial stiffness, chronic kidney disease and occult atrial arrhythmias—pathophysiological domains where combined vascular and cardiorenal risk reduction may yield the greatest absolute benefit. However, they caution that this age-related signal, though statistically significant, rests on a limited number of comparisons and could reflect chance.

The analysis was not without warning signs. Substantial heterogeneity characterized both endpoints, with I-squared values of 72.8 percent for MI and 63.5 percent for stroke. Sensitivity analyses revealed that nonmatched observational cohorts produced a larger MI association (hazard ratio 0.67) than propensity-matched comparisons (hazard ratio 0.87), a statistically significant difference that suggests residual confounding and treatment-selection bias may inflate the apparent benefit in less rigorous study designs. One exploratory subgroup even showed elevated stroke risk among baseline insulin users (hazard ratio 2.33), though this rested on a single comparison and may simply reflect confounding by indication, since insulin use often marks more advanced disease. Applying the GRADE framework, the researchers rated the overall certainty of evidence as very low for both endpoints.

The authors are emphatic that these findings are hypothesis-generating rather than practice-changing. Current American Diabetes Association guidelines already recommend tailoring therapy to individual cardiovascular risk profiles, and both drug classes are well established individually; the new analysis does not mandate dual therapy solely for MI or stroke prevention. Instead, the results suggest that when both agents are already clinically appropriate for a patient’s broader cardiometabolic needs—glycemic control, weight management, heart failure risk—the potential for vascular-specific protection adds a further rationale. Notably, the safety profile of the combination appears favorable, with adverse events remaining largely class-specific: genital mycotic infections and rare euglycemic ketoacidosis for SGLT2 inhibitors, gastrointestinal intolerance for GLP-1 agonists, and a need for careful insulin adjustment to avoid hypoglycemia.

What the field needs next, the researchers argue, are dedicated prospectively powered randomized trials designed from the outset to compare combination therapy against active monotherapy, powered for individual coronary and cerebrovascular events rather than composite MACE. Such trials should capture stroke subtypes, fatal versus nonfatal events, and the sequencing question of simultaneous initiation versus sequential add-on. Until then, this meta-analysis offers a compelling physiological preview: two blockbuster drug classes, each famous in its own right, may protect the heart and the brain through complementary, nonredundant mechanisms—and the patients who stand to gain the most from putting them together may be older adults at high cerebrovascular risk.

Subject of Research: The effect of combined SGLT2 inhibitor and GLP-1 receptor agonist therapy on myocardial infarction and stroke risk in adults with type 2 diabetes

Article Title: Effect of Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists on Myocardial Infarction and Stroke in Type 2 Diabetes: A Systematic Review and Meta-Analysis

Article References: Ghafoury, R., Naghshbandi, M., Malek, M., Kalra, S., Ismail-Beigi, F., & Khamseh, M. E. (2026). Effect of Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists on Myocardial Infarction and Stroke in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes Therapy. https://doi.org/10.1007/s13300-026-01911-2

Image Credits: AI Generated

DOI: 10.1007/s13300-026-01911-2

Keywords: SGLT2 inhibitors, GLP-1 receptor agonists, type 2 diabetes, myocardial infarction, stroke, combination therapy, meta-analysis, cardiovascular outcomes, Diabetes Therapy, ischemic stroke, cardiometabolic medicine, GRADE certainty

The critique responds to a systematic review and meta-analysis that combined results from 21 randomized controlled trials involving 3,417 people with type 1 diabetes. That analysis reported statistically significant improvements in several cardiometabolic measures when GLP-1RAs were added to insulin, including systolic and diastolic blood pressure, low-density lipoprotein cholesterol, C-reactive protein, body weight, body-mass index and HbA1c. The reported weighted mean difference in HbA1c was −0.21 percentage points, a relatively small average reduction but one that may still matter clinically when combined with weight loss or lower insulin requirements. The responding authors commend the breadth of the review and its use of the PRISMA 2020 framework for systematic reviews. However, they say that the absence of a systematic evaluation of hypoglycemia prevents a balanced assessment of the treatment’s benefit-to-risk ratio. For an intervention layered onto insulin, they argue, low blood glucose should be treated as a central safety endpoint rather than a secondary detail.

The biological rationale for the warning lies in how GLP-1RAs alter glucose regulation. These medicines mimic the activity of glucagon-like peptide-1, a hormone released by the intestine after eating. In people with functioning pancreatic beta cells, GLP-1 signaling can enhance insulin secretion when glucose levels are elevated, suppress glucagon release after meals and slow gastric emptying, reducing the speed at which glucose enters the bloodstream. In type 1 diabetes, beta-cell insulin production is severely impaired or absent, so the glucose-lowering effect of a GLP-1RA occurs in a system already controlled by externally administered insulin. Suppressing post-meal glucagon may reduce one of the body’s defenses against falling glucose, while slower gastric emptying can create a mismatch between the timing of food absorption and the action of injected insulin. The drugs may also reduce appetite and food intake, potentially changing carbohydrate consumption without an immediate, carefully adjusted reduction in insulin. These interacting effects make dose, timing, meals, exercise and individual physiology especially important.

Evidence from the ADJUNCT ONE trial illustrates why the issue has become contentious. In that randomized trial, people with type 1 diabetes received liraglutide, a GLP-1RA, in addition to insulin. At the 1.8-milligram dose, symptomatic hypoglycemia occurred at a rate of 16.5 events per patient per year, compared with 12.3 events per patient per year among participants receiving placebo. The higher rate was not the only concern: increased hyperglycemia with ketosis was also observed, leading investigators to conclude that the clinical usefulness of liraglutide in this population was limited. Ketosis occurs when the body begins producing ketone bodies because it cannot use glucose effectively; in type 1 diabetes, substantial ketone accumulation can progress to diabetic ketoacidosis, a medical emergency. The combination of low-glucose events and ketosis is particularly challenging because reducing insulin to prevent hypoglycemia can, if done too aggressively or without adequate monitoring, increase the risk of inadequate insulin delivery and ketone production.

The ADJUNCT TWO trial provided a similar signal at a lower liraglutide dose. Symptomatic hypoglycemia occurred at 21.3 events per patient per year with 1.2 milligrams of liraglutide, compared with 16.6 events per patient per year with placebo. Event rates expressed per patient-year account for different follow-up durations and estimate how many episodes would occur if one participant were observed for a full year, but they do not by themselves reveal whether the events were mild, nocturnal, recurrent or severe enough to require outside assistance. That distinction matters because “hypoglycemia” can cover a wide range of experiences, from a measurable glucose reduction with few symptoms to confusion, seizure, loss of consciousness or the need for emergency treatment. The authors therefore emphasize that insulin doses may need careful adjustment whenever a GLP-1RA is introduced, increased or stopped. A treatment that improves average glucose can still worsen short-term glucose instability if the insulin regimen, meal pattern or counter-regulatory responses are not considered.

The critique also points to real-world safety signals identified in the US Food and Drug Administration’s Adverse Event Reporting System, or FAERS, across several GLP-1RA medicines. Such databases can detect patterns that deserve investigation, but they cannot establish incidence or prove that a drug caused an event. Reports may be influenced by publicity, prescribing volume, patient characteristics and incomplete information. Even so, the authors say these signals add to the reason for demanding more consistent trial reporting. A previous meta-analysis of GLP-1RAs as add-on therapy did not find a statistically significant increase in severe hypoglycemia across 13 studies. But a non-significant pooled result is not equivalent to evidence that no risk exists. Trials may differ in their definitions, glucose-monitoring methods, insulin-adjustment protocols, participant populations and thresholds for recording events. If severe episodes are rare, studies may also lack the statistical power to detect meaningful differences. Combining unlike measurements can make a genuine safety signal appear smaller or disappear altogether.

The authors propose that future systematic reviews should define hypoglycemia in advance as a primary safety outcome and divide it into clinically informative categories. They recommend separating mild, moderate and severe episodes, distinguishing nocturnal from daytime events, and analyzing results by GLP-1RA agent and dose. They also support use of the International Hypoglycemia Study Group’s three-level classification, which is designed to standardize reporting across clinical trials. Level 1 corresponds to a glucose concentration of 3.9 millimoles per liter or less, equivalent to 70 milligrams per deciliter, and signals a threshold at which action may be needed. Level 2 is glucose below 3.0 millimoles per liter, or 54 milligrams per deciliter, a level considered clinically significant. Level 3 does not depend on a specific glucose measurement: it describes severe cognitive impairment in which a person needs help from another individual to recover. This framework has been endorsed by major diabetes organizations and the European Medicines Agency, making it a practical common language for comparing studies.

Standardized reporting could also help researchers answer questions that average event counts conceal. Are low-glucose episodes concentrated after meals, overnight or during exercise? Do they occur primarily during dose escalation, when appetite and carbohydrate intake are changing? Are some agents or doses associated with more events than others? Does continuous glucose monitoring identify substantially more level 1 or level 2 episodes than conventional finger-stick testing? And do people with reduced awareness of hypoglycemia experience fewer symptoms before glucose reaches dangerous levels? These details could influence how doctors select patients, adjust basal and mealtime insulin, counsel about food and physical activity, and monitor treatment after initiation. They could also clarify whether a reduction in HbA1c reflects genuinely improved glucose control or an average produced by alternating lower glucose with episodes of hyperglycemia. For patients, the difference is crucial: a lower HbA1c is not automatically safer if it comes at the cost of more severe glucose excursions.

The debate arrives as GLP-1RAs continue to reshape diabetes and obesity medicine, creating pressure to test their usefulness in populations beyond their most established indications. In type 1 diabetes, however, these drugs are not replacing insulin; they are being considered as supplementary therapy, potentially targeting weight, insulin resistance and cardiometabolic risk. That makes the safety context different from treatment in type 2 diabetes, where the body may still produce some insulin and the risk of severe hypoglycemia can be lower when GLP-1RAs are used without insulin or insulin-releasing drugs. The letter’s central message is therefore one of evidence quality rather than a blanket rejection of the drug class. The authors report no funding or conflicts of interest and generated no new data; their work is a critical appraisal of published evidence. They argue that GLP-1RAs can only be recommended confidently for type 1 diabetes when their metabolic advantages are presented alongside a transparent, standardized account of hypoglycemia. Until then, clinicians and patients may be seeing only half of the treatment equation.

GLP-1RAs have garnered attention for their multifaceted benefits, which extend beyond glycemic control. These agents promote insulin secretion and inhibit glucagon release, ultimately lowering blood glucose levels. However, their impact extends to weight management and cardiovascular health, positioning them as comprehensive treatment options for T2D that also cater to comorbid conditions. The systematic review presents a nuanced understanding that emphasizes both the therapeutic advantages and potential side effects associated with GLP-1RAs.

Conversely, SGLT-2 inhibitors also play a pivotal role in managing T2D. By preventing glucose reabsorption in the kidneys, SGLT-2is enhance urinary glucose excretion, thus aiding blood sugar reduction. Importantly, these agents have been linked to favorable renal and cardiovascular outcomes, which are crucial considerations in the management of patients with T2D, who often exhibit increased risks for these complications. The review meticulously evaluates the balance between these benefits and the risks associated with SGLT-2is, including the potential for urinary tract infections and diabetic ketoacidosis.

The interplay between GLP-1RAs and SGLT-2is offers a complex landscape in which clinicians must navigate risk assessment and patient preferences. Ghosal and Ghosal’s research utilizes a net benefit modeling approach to quantify the value these medications bring over traditional therapies. This model serves as an innovative tool that aids healthcare providers in making informed decisions that align with individual patient needs and circumstances.

In the meta-analysis, the researchers synthesized data from multiple studies to assess the comparative effectiveness of GLP-1RAs and SGLT-2is. The results underscore that while both classes of medications exhibit robust efficacy in glycemic control, they diverge in their additional benefits and side effect profiles. Notably, GLP-1RAs showed superior weight loss effects compared to SGLT-2is, reflecting their dual-impact on both glucose moderation and obesity management, a critical consideration given the obesity epidemic among T2D patients.

Further, cardiovascular health emerges as a paramount concern for those with T2D, which is evidenced by the heightened prevalence of heart disease within this population. Both GLP-1RAs and SGLT-2is have demonstrated cardioprotective properties in various clinical trials. Ghosal and Ghosal’s work elucidates how these medications not only manage insulin resistance but also confer benefits that could help mitigate cardiovascular risk, revealing an opportunity for holistic management strategies.

However, it is essential to recognize that no medication is without risks. The side effects associated with both GLP-1RAs and SGLT-2is cannot be overlooked. The systematic review highlights gastrointestinal issues related to GLP-1RAs as a common concern, which can lead to treatment discontinuation among patients. Similarly, while SGLT-2is offer substantial benefits, risks such as dehydration and renal complications add layers of complexity to patient management strategies.

Equally important is the consideration of patient experience and adherence to therapy. Medication adherence is critical for achieving optimal outcomes in T2D management. The review emphasizes incorporating patient preferences into treatment discussions, which can significantly influence adherence rates. By understanding the nuances of how GLP-1RAs and SGLT-2is meet the lifestyle and health needs of patients, physicians can foster a more collaborative approach to diabetes care.

Moreover, the economic implications of therapy choice are becoming increasingly relevant in healthcare discussions. The net benefit modeling presented in the research provides insights into the cost-effectiveness of GLP-1RAs versus SGLT-2is, which can inform healthcare policy and resource allocation. These findings may influence prescribing practices, particularly as healthcare systems strive to balance budget constraints with the need for effective diabetes management.

The implications of Ghosal and Ghosal’s findings are manifold. As clinicians grapple with the complexities of treating T2D, understanding the associated risks and benefits of both GLP-1RAs and SGLT-2is enables a more tailored approach to patient care. The evidence synthesized in the systematic review is a call to action for clinicians to stay informed about these therapies’ evolving profiles, ensuring that patients receive the highest quality of care.

As we look to the future of T2D treatment, continued research and clinical vigilance will be paramount. At the forefront of diabetes management, GLP-1RAs and SGLT-2is represent not just pharmacological interventions but also a deeper understanding of the multifactorial nature of diabetes. Through ongoing analysis and peer-reviewed studies, the medical community can from new therapeutic landscapes that promise to improve health outcomes for millions of patients living with T2D.

In summary, the intersection of efficacy, safety, patient preferences, and economic considerations presents a complex but essential focus for healthcare providers managing T2D. Ghosal and Ghosal’s meta-analysis fills a critical gap in understanding these medications’ comprehensive profiles, encouraging a thoughtful and informed approach to treatment decisions in the evolving landscape of diabetes care.

Subject of Research: Trade-offs of GLP-1RAs and SGLT-2is in Type 2 Diabetes Mellitus.

Article Title: Risk–Benefit Trade-offs of GLP-1RAs and SGLT-2is in Type 2 Diabetes Mellitus (T2D): Systematic Review, Meta-Analysis, and Net Benefit Modeling.

Article References:
Ghosal, S., Ghosal, A. Risk–Benefit Trade-offs of GLP-1RAs and SGLT-2is in Type 2 Diabetes Mellitus (T2D): Systematic Review, Meta-Analysis, and Net Benefit Modeling.
Diabetes Ther (2025). https://doi.org/10.1007/s13300-025-01817-5

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s13300-025-01817-5

Keywords: T2D, GLP-1RAs, SGLT-2is, meta-analysis, risk-benefit analysis, cardiovascular health, diabetes management, treatment adherence, cost-effectiveness.

The nuances of age and treatment interactions further enrich the analysis, indicating that the efficacy of these treatments may vary across different age groups. Interestingly, SGLT2 inhibitors demonstrated a more pronounced cardioprotective effect in older adults compared to their younger counterparts. This may seem counterintuitive, as older patients often have higher hemoglobin A1c levels and accompanying comorbidities that complicate their management; however, the results highlight the potential of SGLT2 inhibitors to mitigate cardiovascular risks even when glycemic control is not the most pronounced.

Conversely, the study found that GLP-1 receptor agonists appeared to provide a greater cardiovascular benefit for younger individuals. This distinction is critical for clinicians prescribing these medications, as it underscores the importance of individualizing therapy based on a patient’s age and specific health needs. The current landscape of diabetes management is increasingly recognizing the significance of treating not only hyperglycemia but also the associated cardiovascular risks — a shift that could lead to improved health outcomes.

Both SGLT2 inhibitors and GLP-1 receptor agonists operate through different mechanisms to confer their benefits. SGLT2 inhibitors work by inhibiting the reabsorption of glucose in the kidneys, leading to increased glucose excretion and a reduction in blood sugar levels. This mechanism not only aids in glycemic control but also contributes to weight loss, lowering blood pressure and potentially reducing cardiovascular workload.

GLP-1 receptor agonists, on the other hand, function by enhancing glucose-dependent insulin secretion, slowing gastric emptying, and promoting satiety. Their multifaceted approach makes them a valuable option for patients struggling with weight management alongside diabetes, as obesity is another significant risk factor for cardiovascular events. The integration of these agents into clinical practice can transform the standard of care for type 2 diabetes patients, enhancing both their metabolic control and cardiovascular health.

As the results of this meta-analysis continue to resonate within the medical community, the implications extend beyond therapeutic recommendations. They could inform public health policies aimed at preventing cardiovascular diseases, especially among high-risk populations like those with diabetes. The potential for tailored treatments based on age-related responses could lead to targeted awareness campaigns, enhancing the engagement of patients in their own healthcare.

Moreover, the significance of the study may prompt further research into the biological mechanisms that underpin age-related differences in treatment responses. Understanding why older adults benefit more from SGLT2 inhibitors while younger adults derive more cardiovascular protection from GLP-1 receptor agonists could open new avenues for research and innovative treatment strategies. This could lead to the development of combination therapies that maximize benefits across age demographics.

There is also the question of accessibility and adherence to these therapies among diverse populations. Ensuring that these groundbreaking medications are within reach for all patients, regardless of socioeconomic status, will be vital. Health care providers must strive to educate their patients about these options, considering not just the clinical efficacy but also the affordability and availability of such treatments in different healthcare settings.

While the potential benefits of SGLT2 inhibitors and GLP-1 receptor agonists are immensely promising, challenges remain in their broader implementation. Clinicians must be thorough in evaluating patient histories, including existing cardiovascular conditions and other comorbidities, to ensure the safe use of these treatments. The role of underlying health issues, such as renal function, is also crucial to monitoring as these medications can further complicate treatment in certain patients.

As this research is disseminated widely, it will be critical for the medical community to keep abreast of the evolving clinical guidelines that may emerge. The endorsement of these therapies as essential components in diabetes management will likely continue to grow, reshaping the landscape of cardiovascular prevention strategies. In the years to come, the focus will be on harnessing these insights into clinical practice, ensuring that each patient receives the most effective and tailored care possible.

In conclusion, the network meta-analysis underscores a crucial development in our understanding of the crossover benefits of diabetes medications on cardiovascular health. As the scientific community pushes forward, researchers, clinicians, and patients alike must remain engaged and informed about the changing paradigm in diabetes management. The collaboration between these stakeholders will be essential in realizing the full potential of these therapies, paving the way for a healthier future for individuals with type 2 diabetes.

Subject of Research: Cardiovascular effects of SGLT2 inhibitors and GLP-1 receptor agonists in diabetes management
Article Title: Meta-Analysis Explores Cardiovascular Benefits of Diabetes Medications
News Publication Date: 2024-03-15
Web References: N/A
References: N/A
Image Credits: N/A

Keywords: SGLT2 inhibitors, GLP-1 receptor agonists, cardiovascular health, type 2 diabetes, systematic review, network meta-analysis, glycemic control, age interactions.